People · Operator
Named in public records as an officer, director or promoter · active 2021–2023 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nuvectis Pharma, Inc. | — | Biotechnology | Series B | $15.9M | $259.4M | 2022 |
| Centry Pharma, Inc. | — | Pharmaceuticals | Series A | $11.3M | $234.3M | 2021 |
| Lirum Therapeutics, Inc. | — | Biotechnology | Series A | $6.3M | $64.8M | 2023 |
Kenneth Hoberman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kenneth Hoberman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ron Bentsur | 2 | 4 |
| Matthew Kaplan | 2 | 3 |
| Shay Shemesh | 2 | 2 |
| James Oliviero | 2 | 2 |
| Enrique Poradosu | 2 | 2 |
| Ivan Bergstein | 1 | 2 |
| Uri Ben Or | 1 | 2 |
| Michael Carson | 1 | 1 |
| Daniel Hume | 1 | 1 |
| Mark Sard | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.